Johnson & Johnson Cert.Deposito Arg.Repr. 0.2 Shs News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Trading-Depot	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Trading-Depot

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

29.10.25	Johnson & Johnson announces first head-to-head study comparing IMAAVY™ with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting (EN, Johnson & Johnson)
28.10.25	Johnson & Johnson to Advance Robotics Development with NVIDIA Isaac for Healthcare (EN, Johnson & Johnson)
27.10.25	Johnson & Johnson Advances Polyphonic™ AI Fund for Surgery for Data-Driven Healthcare (EN, Johnson & Johnson)
27.10.25	New study reveals substantial unmet need in psoriasis, shows strong patient and provider preference for highly effective oral treatments with favorable safety profile (EN, Johnson & Johnson)
27.10.25	Icotrokinra maintains standout combination of therapeutic benefit and a favorable safety profile in once-daily pill through 28 weeks in ulcerative colitis (EN, Johnson & Johnson)
27.10.25	TREMFYA® (guselkumab), the first and only IL-23 inhibitor with a fully subcutaneous treatment regimen, demonstrates durable remission in Crohn’s disease at two years (EN, Johnson & Johnson)
25.10.25	Published in The Lancet: Nipocalimab significantly decreased Sjögren’s disease (SjD) activity and severity through substantial reduction in Sjögren’s-related autoantibodies (EN, Johnson & Johnson)
24.10.25	Johnson & Johnson MedTech Highlights Newest Impella Heart Pump and Long-Term Survival Data at TCT 2025 (EN, Johnson & Johnson)
24.10.25	Icotrokinra long-term results affirm promise of targeted oral peptide with high rates of durable skin clearance and favorable safety profile in difficult-to-treat scalp and genital psoriasis (EN, Johnson & Johnson)
20.10.25	Johnson & Johnson’s INLEXZO™ (gemcitabine intravesical system) plus cetrelimab delivers strong pre-surgical results in patients with muscle invasive bladder cancer scheduled for radical cystectomy (EN, Johnson & Johnson)
19.10.25	Subcutaneous amivantamab delivers promising 45 percent overall response rate with median duration of 7.2 months in recurrent or metastatic head and neck cancer (EN, Johnson & Johnson)
16.10.25	TECVAYLI® plus DARZALEX FASPRO® combination regimen significantly improves progression-free survival and overall survival versus standard of care (EN, Johnson & Johnson)
15.10.25	Johnson & Johnson enters new era in solid tumors at ESMO 2025 with promising data across multiple cancer types (EN, Johnson & Johnson)
14.10.25	Johnson & Johnson announces intent to separate its Orthopaedics business (EN, Johnson & Johnson)
14.10.25	Johnson & Johnson reports Q3 2025 results; raises 2025 sales outlook (EN, Johnson & Johnson)
13.10.25	Johnson & Johnson Launches INHANCE INTACT™: A Total Shoulder Replacement System Designed for Tissue-Sparing Surgery Providing Day-One Post-Op Mobility (EN, Johnson & Johnson)
10.10.25	Johnson & Johnson Initiates CORE-VA Registry to Advance Ventricular Arrhythmia Ablation Care* (EN, Johnson & Johnson)
10.10.25	Johnson & Johnson to highlight breadth of its major depressive disorder portfolio at 2025 ECNP Congress (EN, Johnson & Johnson)
08.10.25	U.S. FDA approves SIMPONI® (golimumab) for the treatment of pediatric ulcerative colitis (EN, Johnson & Johnson)
07.10.25	Icotrokinra data in ulcerative colitis show potential for a standout combination of therapeutic benefit and a favorable safety profile in once-daily pill (EN, Johnson & Johnson)
07.10.25	TREMFYA® (guselkumab) is first and only IL-23 inhibitor to demonstrate sustained clinical and endoscopic outcomes with a fully subcutaneous regimen through 48 weeks in ulcerative colitis (EN, Johnson & Johnson)
07.10.25	Johnson & Johnson Unveils New Data Demonstrating Superior Clarity of Vision and Comfort of ACUVUE OASYS MAX 1-Day for ASTIGMATISM, and MULTIFOCAL for ASTIGMATISM Contact Lenses (EN, Johnson & Johnson)
29.09.25	U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor (EN, Johnson & Johnson)
24.09.25	The Johnson & Johnson Foundation Announces $5 Million Expanded Investment in Africa Frontline First Catalytic Fund to Strengthen the Community Health Workforce (EN, Johnson & Johnson)
22.09.25	Johnson & Johnson’s investigational seltorexant shows numerically higher response in patients with depression with insomnia symptoms, with fewer side effects compared to quetiapine XR (EN, Johnson & Johnson)
21.11.22	Form 4 200406 (RSS)
15.11.22	Form SC TO-T 200406 (RSS)
07.11.22	Form SC TO-C 200406 (RSS)
04.11.22	Form 4 200406 (RSS)
03.11.22	Form SC TO-C 200406 (RSS)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	97.10	4.95 %	K V
Swisscom	592.00	2.60 %	K V
Swiss Re	149.45	0.64 %	K V
ABB	59.96	0.60 %	K V
Swiss Life Hldg	879.60	0.55 %	K V
Sika	157.10	-0.63 %	K V
CieFinRichemont	160.60	-0.77 %	K V
Lonza Grp	558.40	-1.27 %	K V
Nestle	77.45	-1.30 %	K V
Kuehne+Nagel Int	154.40	-1.91 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Johnson & Johnson Cert.Deposito Arg.Repr. 0.2 Shs Aktie VALOR 942236 / ISIN ARDEUT110236

Nachrichten zu Johnson & Johnson Cert.Deposito Arg.Repr. 0.2 Shs

Aktien Top/Flop

Meistgelesene Nachrichten